Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Salvianolic acid A sodium is a sodium salt of salvianolic acid A, a highly bioactive polyphenolic compound naturally derived from the root of *Salvia miltiorrhiza* (Danshen). It is being developed as an intravenous injection for the treatment of cardiovascular conditions, including coronary artery disease and angina pectoris. The compound is recognized for its potent antioxidant properties, ability to inhibit platelet aggregation, and protective effects on vascular endothelial cells. By reducing oxidative stress and improving microcirculation, it aims to mitigate myocardial ischemia-reperfusion injury and stabilize atherosclerotic plaques. Clinical development in China has progressed through Phase 1 trials evaluating safety, tolerability, and pharmacokinetics in healthy volunteers.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on salvianolic acid A sodium.